Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 12 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8664193

    Compositions and methods for inhibiting expression of factor VII gene

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted

  2. US 8614198

    Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use

    Alnylam Pharmaceuticals, Inc. · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted

  3. US 8598139

    Lipid formulated dsRNA targeting the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  4. US 8598333

    SiRNA silencing of genes expressed in cancer

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  5. US 8592570

    Compositions and methods for inhibiting expression of an RNA from West Nile virus

    Alnylam Pharmaceuticals, Inc. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  6. US 8592571

    RNAi modulation of APOB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  7. US 8575327

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted

  8. US 8546554

    Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted

  9. US 8546143

    Compositions and methods for inhibiting expression of a target gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted

  10. US 8507455

    Folate conjugates

    Alnylam Pharmaceuticals, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  11. US 8507663

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  12. US 8507661

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  13. US 8470799

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 25, 2013 · Expires Jun 20, 2033

    granted

  14. US 8470988

    Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety

    Alnylam Pharmaceuticals, Inc. · Granted Jun 25, 2013 · Expires Jun 20, 2033

    granted

  15. US 8450467

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted May 28, 2013 · Expires May 23, 2033

    granted

  16. US 8445665

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted May 21, 2013 · Expires May 16, 2033

    granted

  17. US 8420799

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Apr 16, 2013 · Expires Apr 11, 2033

    granted

  18. US 8410073

    Methods and compositions for prevention or treatment of RSV infection

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2013 · Expires Mar 28, 2033

    granted

  19. US 8410261

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2013 · Expires Mar 28, 2033

    granted

  20. US 8404862

    Ligand-conjugated monomers

    Alnylam Pharmaceuticals, Inc. · Granted Mar 26, 2013 · Expires Mar 21, 2033

    granted

  21. US 8350021

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Jan 8, 2013 · Expires Jan 3, 2033

    granted

  22. US 8344126

    Compositions and methods for inhibiting expression of XBP-1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 1, 2013 · Expires Dec 27, 2032

    granted

  23. US 8344125

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jan 1, 2013 · Expires Dec 27, 2032

    granted

  24. US 8334273

    Compositions and methods for inhibiting expression of factor VII gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.